Ulcerative Colitis Clinical Trials in Phoenix

Showing 101-120 of 317 trials

Osia 2 Pediatric Expansion Study

NCT05000931

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

Mixed Hearing LossSingle-Sided DeafnessConductive Hearing Loss

Cochlear50 participantsStarted Jan 2022

Phoenix, Arizona, United States • Palo Alto, California, United States • San Diego, California, United States +4 more locations

COMPLETED108 miles

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308

The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Ulcerative Colitis and Crohn's Disease

Takeda5,302 participantsStarted Mar 2015

Birmingham, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +284 more locations

Osia 2 Pediatric Expansion Study

Entyvio (Vedolizumab) Long Term Safety Study

Ulcerative Colitis Trials in Other Cities

Study of OMNI System in OAG (GEMINI)

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Observational Study of Obstructive Lung Disease (NOVELTY)

Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

Other Conditions in Phoenix